Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C42H36O20.Ca |
| Molecular Weight | 900.801 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].[H][C@@]1(C2=CC=CC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=C2C(=O)C4=C1C=C(C=C4O)C([O-])=O)[C@]5([H])C6=C(C(=O)C7=C5C=C(C=C7O)C([O-])=O)C(O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)=CC=C6
InChI
InChIKey=JQVYZJIFFAHQKX-YHPXQAAXSA-L
InChI=1S/C42H38O20.Ca/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46;/h1-10,23-26,31-32,35-38,41-48,51-54H,11-12H2,(H,55,56)(H,57,58);/q;+2/p-2/t23-,24-,25-,26+,31-,32-,35+,36+,37-,38-,41-,42-;/m1./s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21471799 | https://www.ncbi.nlm.nih.gov/pubmed/19393247
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21471799 | https://www.ncbi.nlm.nih.gov/pubmed/19393247
Sennoside B is a member of the class of sennosides that used as the laxative. Sennosides are used all over the world as a treatment for constipation. Sennosides are hydroxyanthracene glycosides derived from Senna leaves. The phytoconstituents principally responsible for its characteristic action are two anthraquinone glycosides namely; Sennoside A and Sennoside B. Sennoside A and B together are responsible for up to 40 – 60% activity of crude senna. They have identical molecular weights and formulae and are in fact diastereomers with the same substituent (H) located in opposite directions. Sennoside B has reported that it has inhibitory effects on PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells.
Approval Year
Sample Use Guides
Adults and children 12 years of age or older - 2 tablets once a day starting dose.
Each tablets contains 7.5 gm of Sennoside B.
Route of Administration:
Oral
Activation of cell metabolism and proliferation as reflected by NAD-dependent dehydrogenase activity was determined via chromogenic reduction of MTT. Osteosarcoma cells in a 96-well plates were allowed to reach 50% confluence (5×10^3 cells/well), starved for 24 h and incubated with different concentrations of sennoside B or vehicle (final concentration 0.5% DMSO) in the absence or presence of PDGFBB (20 ng/ml) in quintuplicate. After 24 and 48 h, cellswere incubated with 0.5 mg/ml MTT for 2 h at 37 °C. Formazan crystals resulting from MTT reduction were dissolved by adding 200 μl DMSO and gently agitating for 20 min. The absorbance of the supernatant was then measured spectrophotometrically at 570 nm using an ELISA reader.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000183993
Created by
admin on Sat Dec 16 08:33:38 GMT 2023 , Edited by admin on Sat Dec 16 08:33:38 GMT 2023
|
PRIMARY | |||
|
73416392
Created by
admin on Sat Dec 16 08:33:38 GMT 2023 , Edited by admin on Sat Dec 16 08:33:38 GMT 2023
|
PRIMARY | |||
|
1I3N1X545L
Created by
admin on Sat Dec 16 08:33:38 GMT 2023 , Edited by admin on Sat Dec 16 08:33:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
